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DObjective: Transcatheter valve-in-valve implantation has emerged as an option, in addition to reoperative sur-
gical aortic valve replacement, to treat failed biologic heart valve substitutes. However, the clinical experience
with this approach is still limited. We report the comprehensive experience of transcatheter valve-in-valve im-
plantation in the Nordic countries from May 2008 to January 2012.
Methods:A total of 45 transcatheter aortic valve-in-valve implantations were performed during the study period
in 11 centers. The mean age of the patients was 80.6 years (range, 61-91), 26 were male and 19 were female, and
the mean EuroSCORE, EuroSCORE II, and Society of Thoracic Surgeons score was 35.4, 16.3, and 14.6,
respectively. The type of failure was stenosis and combined in 58% (mean and peak aortic valve gradient, 77
and 45 mm Hg, respectively) and regurgitation in 42% of cases. The SAPIEN/XT (Edwards LifeSciences,
Irvine, Calif) and CoreValve (Medtronic Inc, Minneapolis, Minn) system was used in 33 and 12 cases, respec-
tively. The access route was transapical in 25, transfemoral in 17, transaortic in 2, and subclavian in 1 case. The
mean follow-up was 14.4 months. The periprocedural and postoperative outcomes were assessed using the Valve
Academic Research Consortium criteria.
Results: No intraprocedural mortality occurred. The technical success rate was 95.6% (1 second valve implan-
tation, 1 conversion to open surgery). The all-cause 30-day mortality was 4.4% (1 cardiac-related and 1 aspi-
ration pneumonia). The major complications within 30 days included stroke in 2.2%, periprocedural
myocardial infarction in 4.4%, and major vascular complication in 2.2% of patients. At 1 month, all but 1
patient had either no or mild paravalvular leakage, with a mean and peak valve gradient of 17 mm Hg (range,
4-38) and 30 mm Hg (range, 7-68), respectively. The mean gradient was greater than 20 mm Hg in 17% of
patients and remained unchanged at 12 months. The 1-year survival was 88.1%.
Conclusions: Transcatheter valve-in-valve implantation is widely performed, albeit in small numbers, in most
centers in the Nordic countries. The short-term results were excellent in this high-risk patient population, demon-
strating a low incidence of device- or procedure-related complications. However, a considerable number of pa-
tients were left with suboptimal systolic valve performance with unknown long-term effects, warranting close
surveillance after transcatheter valve-in-valve implantation. (J Thorac Cardiovasc Surg 2013;146:1047-54)Heart valve replacement with a biologic valve prosthesis is
an accepted treatment modality, especially for elderly
patients, and a trend has been seen toward choosing bio-
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late degenerative valve failure and dense calcification
that, at times, results in the need for reoperation.2-4
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Abbreviations and Acronyms
ID ¼ internal diameter
TAVI ¼ transcatheter aortic valve implantation
TEE ¼ transesophageal echocardiography
THV ¼ transcatheter heart valve
VinV ¼ valve-in-valve
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Dminimally invasive procedure that can offer an alternative to
reoperative open surgery. Several reports have suggested
that, in selected patients, the off-label use of transcatheter
VinV replacement is feasible, with acceptable early re-
sults.5-10 The experience is, however, still limited,
particularly with regard to the safety of implantation of
the transcatheter heart valve (THV) into different types of
failed bioprostheses, the hemodynamic performance, and
longer term outcomes. In addition, comparative data are
needed in terms of the feasibility, safety, and performance
of the different THV devices.
The Nordic Valve-in-Valve registry was initiated with the
objectives to further explore the utility of the VinV concept
for the aforementioned issues. In addition, it was designed
to capture all VinV-transcatheter aortic valve implantation
(TAVI) procedures performed in a defined geographic
area and thereby provide a real-world look at the incidence
and prevalence of these procedures.METHODS
Registry Design
The Nordic Valve-in-Valve Registry was initiated in December 2011. It
is an independent, noncommercial physician-founded registry that does not
receive any external funding. The invitation to participate in the registry
was sent to Nordic centers with an active TAVI program, all of whom re-
sponded. The 11 centers that had performed at least 1 VinV-TAVI proce-
dure were all included and contributed their comprehensive experience
to the registry.
The data collection was retrospective using a dedicated case report
form. The collected variables included detailed information of the make
and type of the primary bioprosthesis and their dimensions, which were ob-
tained from published charts.11 The pertinent demographics and patient
risk factors were defined according to the criteria of the EuroSCORE
(ES) registry.12 The baseline hemodynamics of the failed bioprosthesis
was determined by the last transthoracic echocardiographic study obtained
before the procedure. The mechanism of failure was classified as either ste-
nosis or regurgitation, according to the America Society of Echocardiogra-
phy criteria, and deemed to be combined when both stenosis and
regurgitation were at least of moderate degree. The intraprocedural hemo-
dynamic assessment of the degree of postimplantation aortic regurgitation
was determined from transesophageal echocardiography (TEE) or trans-
thoracic echocardiography (in cases performed with local anesthesia)
and/or angiographic assessment. The periprocedural outcome and major
postoperative clinical endpoints were assessed according to the Valve
Academic Research Consortium criteria, apart from defining procedural
success.13 This was defined as successful delivery and deployment with
1 transcatheter heart valve, VinV performance with neither severe stenosis
(peak gradient>60 mm Hg or peak velocity>4 m/s) nor moderate to se-
vere regurgitation, no conversion to open heart surgery, and the patient1048 The Journal of Thoracic and Cardiovascular Surleaving the operating theater or catheterization suite alive. The patients un-
derwent postoperative clinical and echocardiographic follow-up according
to the institutional protocols. High postprocedural gradients were defined
according to the Valve Academic Research Consortium criteria as those
with a mean transvalvular gradients of 20 mm Hg or more.
The ethics committee of the Helsinki University Hospital (Helsinki,
Finland) approved the study protocol.
Patient Characteristics
The study population consisted of 45 patients who had undergone aortic
VinV-TAVI in 11 cardiac surgical centers in the Nordic countries fromMay
2008 to January 2012. Of the 45 patients, 26 were men (57.8%), and the
mean patient age was 80.6 years (range, 61-91). The baseline patient char-
acteristics, including types and sizes of the failed bioprosthesis are listed in
Tables 1 and 2. The mode of failure was classified as valve stenosis or
regurgitation, or both, in 51%, 29%, and 18% of the patients, respectively.
The peak and mean preoperative gradient was 76.7 16.5 mmHg and 44.8
 11.1 mm Hg, respectively, and the valve opening area was 0.59  0.14
cm2 (patients with aortic regurgitation were excluded). The mean logistic
ES, ES II, and Society of Thoracic Surgeons (STS) score was 35.4 
16.1, 16.3  8.8, and 15.0  10.8, respectively. Of the 45 patients, 33 un-
derwent the procedure with the Edwards SAPIEN/XT device (Edwards
LifeSciences, Irvine, Calif) and 12 with the CoreValve device (Medtronic
Inc, Minneapolis, Minn). The patients did not differ in their baseline char-
acteristics between device groups, apart from more patients being preoper-
atively in New York Heart Association class IV in the SAPIEN group
(42% vs 18%, P ¼ .032).
Statistical Analysis
Qualitative data are expressed as frequencies and percentages, and dif-
ferences between the device groups were compared using the chi-square
test or Fisher’s exact test, as appropriate. Normally distributed quantitative
data are expressed as the mean standard deviation and skewed data as the
median and interquartile range (first quartile minus third quartile). Contin-
uous variables and proportions were compared using the Mann-Whitney
nonparametric U test or Student’s t test, as appropriate. Late survival was
assessed using Kaplan-Meier analysis. Differences with a 2-sided
P<.05 were considered statistically significant. The SPSS, version 17.0
(IBM, Armonk, NY), was used for the statistical calculations.RESULTS
Procedural Characteristics and Results
Table 3 lists the procedural data and immediate out-
comes. The device sizes used were 23 mm in 76% of the
SAPIEN and 26 mm in all CoreValve VinV implantations
(Table 3). For the SAPIEN, the transapical access route
was the most predominant (76%). In contrast, all but 1 Cor-
eValve was implanted transfemorally. General anesthesia
and TEE monitoring were used for most SAPIEN proce-
dures but less frequently for CoreValve (94% vs 42%,
P¼ .001; and 94% vs 33%, P¼ .001, respectively). Preim-
plantation valvuloplasty was performed in 33% of the
procedures.
No procedural mortality occurred. The technical success
rate was 96% (43 of 45). One patient with a CoreValve de-
vice in a 23-mm Mitroflow (Sorin Group, Vancouver,
British Columbia, Canada) prosthesis underwent a second
valve implantation owing to a malposition of the first im-
planted CoreValve. The other technical failure resultedgery c November 2013
TABLE 1. Demographics and preoperative data
Variable All patients (n ¼ 45) SAPIEN (n ¼ 33) CoreValve (n ¼ 12) P value
Gender .467
Male 26 (58) 18 (55) 8 (67)
Female 19 (42) 15 (45) 4 (33)
Age (y) 80.6 (61-91) 80.0  5.6 79.7  8.4 .187
Interval from sAVR (y) 8.7  3.5 8.9  3.7 8.0  2.9 .214
sAVR type .210
Stented pericardial 21 (47) 17 (52) 4 (33)
Stented porcine 16 (28) 12 (36) 4 (33)
Stentless porcine 5 (11) 3 (9) 2 (17)
Homograft 3 (7) 1 (3) 2 (17)
ID* (mm) .600
19 10 (23) 8 (24) 2 (20)
19-21 20 (47) 14 (42) 6 (60)
21 13 (30) 11 (33) 2 (20)
Unknowny 2 — 2
Failure mode .140
Stenosis 23 (51) 16 (48) 7 (58)
Regurgitation 13 (29) 8 (24) 5 (42)
Combined 8 (18) 8 (24) —
Unknown 1 (2) 1 (3) —
EuroSCORE
Logistic 35.4  16.1 37.3  16.6 28.4  12.5 .263
II 16.3  8.8 17.4  9.4 12.7  5.5 .153
STS score 15.0  10.8 15.1  10.6 14.8  5.5 .387
NYHA class .032z
I — — —
II — — —
III 30 (67) 19 (58) 11 (92)
IV 15 (33) 14 (42) 1 (8)
LVEF (%) 46.3  12.8 45.5  13.1 48.3  12.7 .761
LVEF<40% 14 (31) 11 (34) 3 (25) .552
Mitral valve regurgitation .523
None or trace 11 (24) 7 (21) 4 (33)
Mild 26 (58) 20 (61) 6 (50)
Moderate 5 (11) 3 (9) 2 (17)
Moderate to severe 3 (7) 3 (9) 0 (0)
Previous MI 6 (13) 6 (19) 0 (0) .107
CVD 8 (18) 6 (18) 2 (17) .906
Diabetes 8 (18) 4 (12) 4 (33) .100
Chronic renal disease 9 (20) 6 (18) 3 (25) .532
Peripheral atherosclerosis 9 (20) 8 (24) 1 (8) .331
COPD 9 (20) 5 (16) 4 (33) .214
>1 Open heart surgery 5 (11) 1 (3) 4 (13) .004z
Data presented as number of patients (%), mean  standard deviation, or median (interquartile range). sAVR, Surgical aortic valve replacement; ID, internal diameter; STS,
Society of Thoracic Surgeons; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; MI, myocardial infarction; CVD, cerebrovascular
disease; COPD, chronic obstructive pulmonary disease. *ID of the valve prosthesis as labeled by the manufacturer. yOne root xenograft and one homograft. zStatistically
significant.
Ihlberg et al Acquired Cardiovascular Disease
A
C
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leaflet dysfunction of a SAPIEN device in a patient with
21-mm Freestyle prosthesis (Medtronic). That patient un-
derwent a successful open surgical correction 3 days later.
Two patients developed periprocedural myocardial infarc-
tion. Major vascular complications consisted of an occlu-
sive external iliac artery dissection in 1 patient that wasThe Journal of Thoracic and Carmanaged by endovascular stent grafting. At the end of the
procedure, none of the patients had more than mild intra-
valvular aortic insufficiency, with the exception of the pre-
viously mentioned patient with leaflet dysfunction. One
patient had a moderate paravalvular leak. A greater number
of patients with the SAPIEN device had no or only trace
paravalvular leaks (82% vs 33%, P ¼ .005).diovascular Surgery c Volume 146, Number 5 1049
TABLE 2. Tissue valves used in the primary surgery
Valve type Trade name Patients (n)
Stented porcine Biocor/Epic 3 (7)
Carpentier Edwards SAV 10 (22)
Mosaic 2 (4)
Mosaic Ultra 1 (2)
Shelhigh 1 (2)
Stented pericardial Mitroflow 15 (33)
Magna 1 (2)
Perimount 4 (9)
Soprano 1 (2)
Stentless porcine Medtronic Freestyle 3 (7)
Toronto SPV 1 (2)
Homograft 3 (7)
Data in parentheses are percentages. SAV, Supra-annular valve; SPV, stentless
porcine valve.
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The mean in-hospital and intensive care unit stay was 8.0
days (range, 2-22) and 1.2 days (range, 0-4), respectively.
The 30-day mortality was 4.4%. One patient who had expe-
rienced a periprocedural myocardial infarction died on the
second postoperative day. She had had a 23-mm SAPIEN
device implanted by way of the transfemoral route in a 23-
mm Freestyle prosthesis. In the autopsy, the left coronary
ostium was found to be partially obstructed by the torn
porcine leaflet of the bioprosthesis. The other patient died
of aspiration pneumonia and respiratory insufficiency. One
patient had a major stroke. A permanent pacemaker was im-
planted in 7% of patients (1 patient with stented and 2 with
stentless valves; 3% SAPIEN vs 17% CoreValve, P¼NS).
The peak and mean transvalvular gradient at 30 days had
decreased to 28.9  14.9 mm Hg and 16.4  8.7 mm Hg,
respectively (Figure 1). These values did not differ between
the SAPIEN and CoreValve groups. A total of 17% of pa-
tients (16% of SAPIEN and 18% of CoreValve) had a
mean valve gradient greater than 20 mm Hg, but included
no patients with aortic insufficiency as the primary failure
mode. At 30 days, 95% of patients were at New York Heart
Association class I or II.
The internal diameter (ID) of the failed bioprostheses, as
given by the manufacturer, was, on average, 2 mm smaller
for the pericardial valves than for the porcine valves (19.7
0.43 mm pericardial vs 21.7 0.31 mm porcine, P¼ .039).
This did not, however, translate to any differences in the 30-
day hemodynamic performance, because the respective
peak and mean valve gradient for the pericardial and
porcine valves was 32.3  14.1 mm Hg vs 29.2  13.1
mm Hg (P ¼ .708) and 17.5  8.2 mm Hg vs 17.0  8.0
mm Hg (P ¼ .695).
Follow-up Data
Themean follow-up periodwas 14.4months (range, 0-43).
The cumulative survival at 6, 12, and 24 months was 93.2%,
88.1%, and84.1%, respectively (Figure2). Seven late deaths1050 The Journal of Thoracic and Cardiovascular Surhave occurred, of which 2 have been cardiac-related
(prosthetic valve endocarditis at 3 months and congestive
heart failure at 22 months) and 3 have been noncardiac-
related (subdural hemorrhage at 8 months, chronic myeloid
leukemia at 8 months, and traumatic head injury at 14
months). The cause of death was unknown for 2 patients.
At 1 year, both the functional and hemodynamic follow-
up status was available for 29 patients. Of these 29 patients,
89.7% remained in New York Heart Association functional
class I or II. The peak and mean valve gradient was 26.8 
11.2 mm Hg and 15.3  7.8 mm Hg, respectively. A mean
valve gradient of 20 mm Hg or greater was measured in
22% of patients, with no correlation to the complication
rates or overall survival.
DISCUSSION
In the Nordic countries, the current annual overall vol-
ume of TAVIs has been estimated to be 850 to 900 cases.
Currently, the VinV-TAVI procedures constitute only 2%
to 3% of the total case volume. This can be expected to
grow with increasing experience in TAVI and because of
a general trend toward lowering the age for the use of a bio-
prosthesis.1 Nevertheless, with few exceptions, the number
of VinV-TAVI implantations for each individual center will
likely remain low. In our report, the caseload averaged 4.5
patients per unit. This was in line with that reported by
Dvir et al,14 in which the case series of 202 patients with
VinV implantations was derived from a total of 38 centers.
Just as with all low-volume procedures, the scientific ev-
idence can be expected be based on multicenter observa-
tional clinical series. Studies with direct comparisons to
the open reoperative aortic valve replacement alternative
are unlikely to be performed. The reported mortality for
an elective redo aortic valve surgery has showed a high vari-
ation from 2% to 30%, which has correlated mostly with
patient-associated risk factors.2,3 Reoperations have been
associated with increased morbidity, longer hospital stays,
and prolonged recovery. VinV-TAVI is a very attractive,
less-invasive, alternative for many of these, particularly
high-risk, patients. The patient selection for these alterna-
tives needs to be weighed carefully and requires an in-
depth understanding of their potential and limits.
Procedural Safety and Efficacy
Our results are in accordance with those from published
single- and multicenter experience demonstrating that
VinV-TAVI is technically feasible and has a safety profile
at least as good as TAVI in the treatment of native aortic valve
stenosis. Because of the high-risk patient group (with an
average logistic ES of 35.4%) that was treated, the observed
4.4% overall mortality was very acceptable. In addition, the
incidence of major complications was relatively low. This is
in keepingwith the firstmulticenter experience using the SA-
PIEN valve reported by Webb et al.6 Their report of 24gery c November 2013
TABLE 3. Perioperative data and immediate outcomes
Variable All patients (n ¼ 45) SAPIEN (n ¼ 33) CoreValve (n ¼ 12) P value
Device size
23 25 (56) 25 (76) — NA
26 19 (42) 7 (21.2) 12
29 1 (2) 1 (3) —
Access route NA
Transapical 25 (56) 25 (76) —
Transfemoral 17 (38) 6 (18) 11 (92)
Transaortic 2 (4) 2 (6.1) —
Subclavian 1 (2) — 1 (8)
General anesthesia 36 (80) 31 (94) 5 (42) .001*
TEE 35 (78) 31 (94) 4 (33) .001*
Predilation valvuloplasty 15 (33) 11 (33) 4 (33) .678
Procedural outcome
Mortality — — —
Technical success 43 (96) 32 (97) 11 (92) .208
Second valve implanted 1 (2) — 1 (8) NA
Intravalvular AI
None or trace 42 (93) 30 (91) 12 (100)
Mild 2 (4) 2 (6) —
Moderate — — —
Severe 1 (2) 1 (2) — .557
Paravalvular AI
None or trace 31 (69) 27 (82) 4 (33)
Mild 13 (29) 6 (18) 7 (58)
Moderate 1 (2) — 1 (8) .005*
Conversion to open surgery 1 (2) 1 (3) — NA
Major vascular complication 1 (2) — 1 (8) NA
Bleeding .692
Major — — —
Minor 6 (13) 4 (12) 2 (17)
Outcome at 30 d
Mortality 2 (4) 2 (6) — NA
ICU stay (d) 1.2  0.7 1.3  0.8 0.9  0.6 .318
Hospital stay (d) 8.0  3.9 7.8  4.3 8.4  2.9 .600
Periprocedural MI 2 (4) 2 (6) — NA
Major stroke 1 (2) 1 (3) — NA
Permanent pacemaker 3 (7) 1 (3) 2 (17) .150
Paravalvular AI .001*
None or trace 34 (79) 29 (94) 5 (42)
Mild 8 (19) 2 (6) 6 (50)
Moderate 1 (2) — 1 (8)
Peak valve gradient (mm Hg) 28.9  14.9 28.7  10.6 29.2  20.9 .070
Mean valve gradient (mm Hg) 16.4  8.7 16.2  6.6 16.7  12.4 .071
Valve area (cm2) 1.3  0.4 1.2  0.3 1.4  0.5 .065
LVEF 49.6  11.7 51.1  10.7 46.6  13.7 .398
NYHA functional class
I 16 (37) 11 (35) 5 (42)
II 22 (51) 15 (48) 7 (52)
III 1 (2) 1 (3) —
IV — — —
Unknown 4 (9) 4 (13) — .796
Data presented as number of patients (%), mean standard deviation, or median (interquartile range). NA, Not available; TEE, transesophageal echocardiography; AI, aortic insuf-
ficiency;MI, myocardial infarction; ICU, intensive care unit; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction. *Statistically significant.
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FIGURE 1. Themean and peak valve gradient 30 days after valve in valve
transcatheter aortic valve implantation for different manufacturer-given in-
ternal diameters (IDs) was 18.3  6.2 mm Hg, 16.4  10.0 mm Hg, and
14.4  7.5 mm Hg and 34.14  9.9 mm Hg, 30.3  16.6 mm Hg, and
25.6 12.3 mmHg for an ID of less than 19 mm, 19 to 21 mm, and greater
than 21 mm, respectively.
FIGURE 2. The overall postoperative survival of the 45 valve in valve
transcatheter aortic valve implantation patients.
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with a mean logistic ES of 30.4%. Similar results were
achieved in a single-center VinV experience with the SA-
PIEN valve for 23 high-risk patients, with no operative mor-
tality.15 In the largest multicenter experience of VinV-TAVI,
most implantations were performed using the CoreValve de-
vice.14 The 30-day mortality was 8.4% in a patient cohort
with a risk profile similar to that in the other cited studies.
However, concerns exist of major procedure-specific
safety hazards with VinV-TAVI. These include device
malposition, an increased risk of coronary obstruction,
especially with certain valve types, and suboptimal systolic
valve function.
The placement of the device inside the bioprosthesis must
be very accurate, because the area of anchoring is very nar-
row and, in the case of a stented bioprosthesis, limits itself
to a circular basal ring. This dictates how much and which1052 The Journal of Thoracic and Cardiovascular Surparts of the THV can expand. To facilitate VinV-TAVI, the
early reports preferred the use of the direct surgical access
(typically transapical) route for better device control and
more accurate placement.6 With the device modifications,
the transfemoral access route has become a widely accepted
alternative. However, a rate of up to 15.3% of initial device
malposition has been reported.14 In our results, only 1 pa-
tient required a second valve implantation because of a
malpositioned first device. It is a matter of debate whether
this result is a reflection of more than 60% use of shorter
surgical access routes.
An increased risk of coronary obstruction has been asso-
ciated with certain valve types, including stented pericardial
valves with a design that has the pericardial leaflet wrapped
outside of the stent frame and stentless valves. Our report
included 15 VinV-TAVI with the stented pericardial valve
described (Mitroflow), with no coronary obstruction
observed. That compares favorably with the previously re-
ported coronary obstruction incidence of 7.7% in VinV im-
plantations inside the Mitroflow prosthesis. Nevertheless,
patients with these valve types should be studied very care-
fully, especially in cases of small aortic root dimensions and
a high supra-annular position of the bioprosthesis.
Computed tomographic angiography with multiplanar re-
constructions is likely the best assessment method.
The stentless valves, including homografts, pose unique
challenges for VinV positioning and deployment because
of their size, lack of radiopaque markers, heterogeneous
design, and implantation techniques. These issues were re-
ported by Bapat et al.15 We suggest that more oversizing
(>10% in the cross-sectional area) is needed because failed
stentless valves have typically not been very calcified and do
not have a frame in which to anchor. Hence, self-expanding
devices that allow for more oversizing but exert less radial
force have been preferred by some investigators in thesegery c November 2013
Ihlberg et al Acquired Cardiovascular Disease
A
C
Dsituations.16 In the presence of severe aortic regurgitation,
the aortic annulus might not be easily delineated. Special
measures could be necessary to create landmarks for secure
valve positioning, such as placing a pigtail catheter in the
base of the sinus or marking the left main coronary ostium
with a guidewire. The risk of complications, even when tak-
ing all precautions, is still most likely greater than with the
stented valves. In our series, with 5 stentless porcine valves,
2 patients experienced major complications, coronary
obstruction in 1 patient and leaflet dysfunction requiring
conversion to an open procedure in 1 patient. The 3 homo-
graft cases were performed without complications.
Valve Sizing and Hemodynamic Function of
VinV-TAVI
Choosing the optimal THV size for the failed bio-
prosthesis is critical for secure fixation and optimal hemody-
namic function. Valve embolization in VinV-TAVI has been
reported. Paravalvular aortic regurgitation seems to have
been less of a problem in the published series of VinV-
TAVI compared with TAVI of native aortic valve stenosis.
However, excessive oversizing can lead to incomplete
expansion of the new valve. This in turn could cause valve
leaflet distortion, affecting systolic hemodynamic function
and potentially limiting the durability of the THV. This
was demonstrated in an in vitro model evaluating the hemo-
dynamic performance of a 23-mmTHV.17 It was shown that,
when implanted in 19- and 21-mmbioprostheses, the incom-
plete stent expansion resulted in leaflet distortion and central
regurgitation. In clinical series, the valve gradients after
VinV-TAVI have been significantly greater than those after
TAVI in the native aortic valve, in which a mean gradient
of less than 10 mm Hg typically can be expected.18
The size of the THVused should match or exceed the ID
of the bioprosthesis. The labeled IDs can be obtained from
published charts.11 However, the exact or ‘‘true’’ ID might
be different from the manufacturer-given ID.19 In the case
of stented valves, the ID is invariably smaller by 1 to 3
mm. Owing to their design, the stented porcine valve pros-
theses typically represent the upper range. This was
also shown in the present study, in which the VinV-
TAVIs on porcine valves had, on average, 2-mm larger
manufacturer-given IDs than the pericardial valves, result-
ing in similar postprocedural valve gradients. In addition,
the actual ID can be decreased further by various disease
processes, such as calcification, fibrosis, and pannus forma-
tion. A thorough preprocedural screening with computed
tomography and TEE is therefore necessary to identify
any discrepancies between the nominal diameters and the
in vivo measurements. However, little is known regarding
the TEE and computed tomography measurements and their
correlation to the actual ID.
It has been postulated that THVs with a ‘‘supra-annular’’
design (eg, CoreValve) could perform hemodynamicallyThe Journal of Thoracic and Carbetter in small valve sizes than an ‘‘intra-annular’’ device
(eg, SAPIEN). This was supported by Dvir et al,14 who
found the SAPIEN device to have greater valve gradients
for manufacturer-given IDs less than 20 mm than did the
CoreValve device. In our experience, we could verify, in
accordance with their results, that close to 20% of patients
will have a mean transvalvular gradient exceeding 20 mm
Hg but could not demonstrate any difference between the
devices.
Role of Balloon Aortic Valvuloplasty
Only a few patients underwent balloon aortic valvulo-
plasty, with seemingly nomajor procedural hazards in terms
of difficulties when crossing the valve or challenges in the
hemodynamic treatment of these patients. In conjunction
with VinV-TAVI, the balloon aortic valvuloplasty can
most likely be reserved for selected patients such as those
with very critical aortic stenosis or with an identified
increased risk of coronary obstruction; performing a root
angiogram with the balloon inflated can be a useful method
of assessing the risk.
Implications for Surgical Aortic Valve Replacement
Practice
The increasing evidence of an acceptable safety profile of
VinV-TAVI will most likely accelerate the trend of choosing
a biologic valve prosthesis instead of a mechanical valve
even for younger patients undergoing primary surgical
aortic valve replacement. For patients who have a high like-
lihood of outliving the estimated durability of their bio-
prosthesis, the surgical aortic valve replacement should be
performed in such a manner that good prerequisites for a
successful future VinV-TAVI exist. The valve size should
be large enough to minimize residual valve gradients and
the risk of primary patient–prosthesis mismatch. This might
change the practice toward performing more aortic root
dilation annuloplasty procedures to accommodate a large
enough valve size. In addition, the chosen primary valve
prosthesis should preferably be of a type not known to
have an increased risk of procedural complications at
VinV-TAVI, most importantly, a low risk of coronary
obstruction.
Study Limitations
The present study had several limitations with respect to
both its design and patient material. As a registry trial, the
data were not audited, and the collected hemodynamic
data had not been core laboratory adjudicated. The number
of patients was still relatively small, precluding additional
analysis of the safety profile of VinV-TAVI in different pri-
mary valve types and comparing the performance of the
available THV devices. The results can be regarded as
hypothesis-generating only. The mean follow-up was
limited to little more than 1 year. Thus, the long-termdiovascular Surgery c Volume 146, Number 5 1053
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Dsequelae of VinV-TAVI, especially with regard to the effect
of high postprocedural valve gradients or durability, could
not be assessed.CONCLUSIONS
VinV-TAVI is a part of the armamentarium in most cen-
ters performing TAVI, albeit in small numbers. In this high-
risk patient population, the early experience has been excel-
lent, with a low incidence of device- or procedure-related
complications. However, a considerable number of patients
had a high transvalvular gradient after the procedure, the
long-term effects of which are unknown. Close long-term
surveillance after VinV-TAVI is needed, especially for pa-
tients known to have suboptimal systolic valve function.
Finally, future larger scale studies are warranted.
The authors thank Janne Jokinen from Helsinki University Hos-
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Discussion
Dr Mathew R. Williams (New York, NY). This is an exciting
procedure that really represents a sweet spot for transcatheter
valves. This is an observational study, your data is well presented,
and to that end I certainly do not have any critiques. However, I
would rather spend the time to discuss procedural and planning
components, because, fortunately now, a lot more of us are able
to do this procedure.
The first question is how have you decided what kind of access
to use in these patients? Initially, the reports suggested that this
should be done with a transapical approach. We have not found
that and have generally been just access driven.
Dr Ihlberg. I would say that the access is completely today up
to the discretion and preference of the operator and also partly for
the device used at the given center. My personal bias is that I still
like the surgical short access, good device maneuvering, and to be
able to land the device exactly on the target. I tend to conceptualize
the procedure as being similar to landing a helicopter onto an air
carrier. Needless to say, we do not have any air carriers in Finland,
and I have never done that myself, but it is just a concept. Still, I
like it, especially when you do valve in valve because of the sort
of small target in which you land it, but I know that, equally
well, people do this transfemorally.
DrWilliams. Is there any reason that this procedure works very
well? There is much less paravalvular leakage than we see in the
native aortic stenosis, which is really one of the Achilles heels
of this procedure. Is there any reason that in most patients this
should not quickly become the standard of care for degenerated tis-
sue valves, even in lower risk patients?
Dr Ihlberg. That is a great question or thought, and I think you
are correctly right in your considerations. I believe that things are
rapidly moving to that direction, so that valve-in-valve TAVImight
even become a default procedure under certain conditions. Thus, if
you do not have any pre-identified risk of coronary obstruction or if
you do not have a primary patient–prosthesis mismatch in these
patients, you can expect to have a reasonable gradient after the pro-
cedure. The results so far in our study and in the other studies, of
which the largest is the global valve-in-valve registry, have been
good.gery c November 2013
